top of page

Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required)

HHS-NIH11

Status:

Active

​

Posted:

Deadline: 

November 2, 2023

Funding

​

Program:

​

Award Floor:

Ceiling:

700000

Match Required?

No

Eligibility

All

States:

Entity Types:

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public & State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations, Nonprofits (with 501(c)(3) status), Nonprofits (without 501(c)(3) status)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Contact

Email:

grantsinfo@nih.gov

Phone:

​

Source Type:

Federal

The purpose of this FOA is to use multidisciplinary approaches to advance basic and clinical research and address key knowledge gaps on psychedelics. Given the therapeutic promise that psychedelics hold as neurotherapeutics, the goal is to systematically evaluate, and understand their mechanism of action and drug-target engagement, along with other translational aspects including their safety, pharmacokinetics/pharmacodynamics, and efficacy, in the context of substance use disorders (SUD).

Tired of searching for grants? Consider a Scouting Report.

bottom of page